• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Ignyte Acquisition Corp.

    2/4/22 11:30:56 AM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials
    Get the next $IGNY alert in real time by email
    SC 13G 1 formsc13g.htm FORM SC 13G Saba Capital Management, L.P.: Form SC 13G - Filed by newsfilecorp.com

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

    Ignyte Acquisition Corp

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    45175H106

    (CUSIP Number)

     

    January 27, 2022

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     [_]  Rule 13d-1(b)

     [X]  Rule 13d-1(c)

     [_]  Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    SCHEDULE 13G

    CUSIP No.

    45175H106


    1

    Names of Reporting Persons

    Saba Capital Management, L.P.

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  [ ]
    (b)  [ ]

    3

    Sec Use Only

     

    4

    Citizenship or Place of Organization

    Delaware

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

    5

    Sole Voting Power

    -0-

    6

    Shared Voting Power

    354,843

    7

    Sole Dispositive Power

    -0-

    8

    Shared Dispositive Power

    354,843

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

    354,843

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    [ ]

    11

    Percent of class represented by amount in row (9)

    6.2%

    12

    Type of Reporting Person (See Instructions)

    PN; IA

           

    The percentages used herein are calculated based upon 5,750,000 shares of common stock outstanding as of February 01, 2021, as disclosed in the company's 8-k filed February 08, 2021

    Page 2 of 8


    SCHEDULE 13G

    CUSIP No.

    45175H106


    1

    Names of Reporting Persons

    Boaz R. Weinstein

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  [ ]
    (b)  [ ]

    3

    Sec Use Only

     

    4

    Citizenship or Place of Organization

    United States

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

    5

    Sole Voting Power

    -0-

    6

    Shared Voting Power

    354,843

    7

    Sole Dispositive Power

    -0-

    8

    Shared Dispositive Power

    354,843

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

    354,843

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    [ ]

    11

    Percent of class represented by amount in row (9)

    6.2%

    12

    Type of Reporting Person (See Instructions)

    IN

           

    The percentages used herein are calculated based upon 5,750,000 shares of common stock outstanding as of February 01, 2021, as disclosed in the company's 8-k filed February 08, 2021

    Page 3 of 8


    SCHEDULE 13G

    CUSIP No.

    45175H106


    1

    Names of Reporting Persons

    Saba Capital Management GP, LLC

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  [ ]
    (b)  [ ]

    3

    Sec Use Only

     

    4

    Citizenship or Place of Organization

    Delaware

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

    5

    Sole Voting Power

    -0-

    6

    Shared Voting Power

    354,843

    7

    Sole Dispositive Power

    -0-

    8

    Shared Dispositive Power

    354,843

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

    354,843

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    [ ]

    11

    Percent of class represented by amount in row (9)

    6.2%

    12

    Type of Reporting Person (See Instructions)

    OO

           

    The percentages used herein are calculated based upon 5,750,000 shares of common stock outstanding as of February 01, 2021, as disclosed in the company's 8-k filed February 08, 2021

    Page 4 of 8


    Item 1.

    (a) Name of Issuer: Ignyte Acquisition Corp

    (b) Address of Issuer's Principal Executive Offices: 640 5th Avenue, 4th Floor, New York, NY 10019

    Item 2.

    (a) Name of Person Filing: Saba Capital Management, L.P., a Delaware limited partnership ("Saba Capital"), Saba Capital Management GP, LLC, a Delaware limited liability company ("Saba GP"), and Mr. Boaz R. Weinstein (together, the "Reporting Persons").  The Reporting Persons have entered into a Joint Filing Agreement, dated February 4, 2022, pursuant to which the Reporting Persons have agreed to file this statement and any subsequent amendments hereto jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.  The filing of this statement should not be construed as an admission that any of the forgoing persons or the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.

    (b) Address of Principal Business Office or, if None, Residence:  The address of the business office of each of the Reporting Persons is 405 Lexington Avenue, 58th Floor, New York, New York 10174.

    (c) Citizenship: Saba Capital is organized as a limited partnership under the laws of the State of Delaware. Saba GP is organized as a limited liability company under the laws of the State of Delaware. Mr. Weinstein is a citizen of the United States.

    (d) Title and Class of Securities: Common stock, $0.0001 Par Value (the "Common Stock").

    (e) CUSIP No.: 45175H106

    Item 3.  If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a) [_] Broker or dealer registered under Section 15 of the Act;

    (b) [_] Bank as defined in Section 3(a)(6) of the Act;

    (c) [_] Insurance company as defined in Section 3(a)(19) of the Act;

    (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940;

    (e) [_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

    (f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

    (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

    (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    Page 5 of 8


    (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

    (j) [_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

    (k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    Item 4. Ownership

    (a) Amount Beneficially Owned:    The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class. N/A

    Item 6. Ownership of more than Five Percent on Behalf of Another Person.  The funds and accounts advised by Saba Capital have the right to receive the dividends from and proceeds of sales from the Common Stock.

    Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. N/A

    Item 8. Identification and classification of members of the group. N/A

    Item 9. Notice of Dissolution of Group.  N/A

    Item 10. Certifications.

     By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Page 6 of 8


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  February 4, 2022

    /s/ Signature  Michael D'Angelo

    Name: Michael D'Angelo

    Title: Chief Compliance Officer

    Boaz R. Weinstein

    By: Michael D'Angelo

    Title: Attorney-in-fact***

    *** Pursuant to a Power of Attorney dated as of November 16, 2015

    Page 7 of 8


    EXHIBIT 1

    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.  The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

    DATED:  February 4, 2022

    SABA CAPITAL MANAGEMENT, L.P.
     
     
    By:  /s/ Michael D'Angelo                                          
    Name: Michael D'Angelo
    Title: Authorized Signatory
     
    SABA CAPITAL MANAGEMENT GP, LLC
     
    By:  /s/ Michael D'Angelo                                          
    Name: Michael D'Angelo
    Title: Authorized Signatory
     
     
    BOAZ R. WEINSTEIN
     
    By:  /s/ Michael D'Angelo                                          
    Title: Attorney-in-fact

    Page 8 of 8


    Get the next $IGNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IGNY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lamond Stephen J bought 5,600 shares, increasing direct ownership by 39% to 19,850 units (SEC Form 4)

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:23 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Lamond Stephen J bought 14,250 shares (SEC Form 4) (Amendment)

    4/A - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Huh Hoyoung bought 45,000 shares, increasing direct ownership by 0.54% to 8,382,742 units

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/25/23 4:05:03 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    SEC Filings

    View All

    SEC Form 8-K filed by Ignyte Acquisition Corp.

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    2/6/24 4:09:01 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 8-K filed by Ignyte Acquisition Corp.

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    1/29/24 5:08:05 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Ignyte Acquisition Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    1/3/24 5:08:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Peak Bio Co., Ltd. to List on NASDAQ Following Successful Business Combination with Ignyte Acquisition Corp.

    Combined Company Scheduled to Commence Trading on NASDAQ Under the Ticker Symbol "PKBO" Peak Bio Co., Ltd. ("Peak Bio"), a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory diseases, today announced the completion of its business combination (the "Business Combination") with Ignyte Acquisition Corp. (NASDAQ:IGNY) ("Ignyte"), a special purpose acquisition company. The transaction was approved at a special meeting of Ignyte's stockholders held on October 25, 2022 (the "Special Meeting"). Ignyte's stockholders also voted to approve all other proposals presented at the Special Meeting. Ignyte's Board of Direct

    11/2/22 7:30:00 AM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Ignyte Acquisition Corp. Stockholders Approve Proposed Business Combination with Peak Bio

    Transaction Expected to Close on October 31, 2022 Ignyte Acquisition Corp. ("Ignyte") (NASDAQ:IGNY), a publicly traded special purpose acquisition company, today announced that Ignyte's stockholders have approved its proposed business combination (the "Business Combination") with Peak Bio Co., Ltd. ("Peak Bio") at a Special Meeting of its stockholders held on October 25, 2022 (the "Special Meeting"). The Special Meeting to be held on October 31, 2022 has been canceled. Approximately 75% of the votes cast at the Special Meeting, representing approximately 75% of Ignyte's outstanding shares of common stock entitled to vote at the Special Meeting, were cast in favor of the proposal to approv

    10/27/22 8:05:00 AM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company

    - Company to be led by Hoyoung Huh, M.D. Ph.D., serial entrepreneur / investor with notable public and private biotech board positions - $25 million private investment in public equity ("PIPE") with participation from leading healthcare institutional investor, Palo Alto Investors (PAI) with additional participation from Peak Bio's CEO, Hoyoung Huh, MD, Ph.D. - Differentiated pipeline includes next generation Neutrophil Elastase Inhibitor targeting AATD / ARDS and robust preclinical ADC oncology platform utilizing Antibody Drug Conjugates - Anticipated cash at closing expected to fully fund the company through 2024 allowing for multiple milestones in ADC program and interim Phase II for A

    4/28/22 4:32:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Ignyte Acquisition Corp.

    SC 13D - Peak Bio, Inc. (0001834645) (Subject)

    3/21/23 5:30:30 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G filed by Ignyte Acquisition Corp.

    SC 13G - Peak Bio, Inc. (0001834645) (Subject)

    2/28/23 4:01:06 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by Ignyte Acquisition Corp. (Amendment)

    SC 13G/A - Peak Bio, Inc. (0001834645) (Subject)

    2/14/23 3:39:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lamond Stephen J bought 5,600 shares, increasing direct ownership by 39% to 19,850 units (SEC Form 4)

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:23 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Lamond Stephen J bought 14,250 shares (SEC Form 4) (Amendment)

    4/A - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Huh Hoyoung bought 45,000 shares, increasing direct ownership by 0.54% to 8,382,742 units

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/25/23 4:05:03 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Financials

    Live finance-specific insights

    View All

    Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company

    - Company to be led by Hoyoung Huh, M.D. Ph.D., serial entrepreneur / investor with notable public and private biotech board positions - $25 million private investment in public equity ("PIPE") with participation from leading healthcare institutional investor, Palo Alto Investors (PAI) with additional participation from Peak Bio's CEO, Hoyoung Huh, MD, Ph.D. - Differentiated pipeline includes next generation Neutrophil Elastase Inhibitor targeting AATD / ARDS and robust preclinical ADC oncology platform utilizing Antibody Drug Conjugates - Anticipated cash at closing expected to fully fund the company through 2024 allowing for multiple milestones in ADC program and interim Phase II for A

    4/28/22 4:32:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials